The Role of Quinolones in Staphylococcal Infection
P. M. Shah
Abstract
P. M. Shah
Abstract
Quinolones are highly active against gram-negative aerobic bacteria, especially enterobacteriaceae. The minimum inhibitory concentrations against, e.g. Escherichia coli are between 0.008-0.03 mg/l for ciprofloxacin, 0.06-0.25 mg/l for norfloxacin, 0.031-1.0 mg/l for ofloxacin, and 0.063-2.0 mg/l for pefloxacin. Against Staphylococcus aureus, higher concentrations are required in vitro: 0.12-0.5 mg/l for ciprofloxacin and ofloxacin, 0.25-4 mg/l for norfloxacin, and 0.06-0.5 mg/l for pefloxacin. These compounds have been shown to be active at similar concentrations also against Staphylococcus epidermidis and both oxacillin-sensitive and resistant Staphylococcus aureus and Staphylococcus epidermidis. Clinical experience (in the order of number of patients treated) has been gathered most extensively with ciprofloxacin, followed by pefloxacin, ofloxacin, norfloxacin, and enoxacin.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Quinolones are highly active against gram-negative aerobic bacteria, especially enterobacteriaceae. The minimum inhibitory concentrations against, e.g. Escherichia coli are between 0.008-0.03 mg/l for ciprofloxacin, 0.06-0.25 mg/l for norfloxacin, 0.031-1.0 mg/l for ofloxacin, and 0.063-2.0 mg/l for pefloxacin. Against Staphylococcus aureus, higher concentrations are required in vitro: 0.12-0.5 mg/l for ciprofloxacin and ofloxacin, 0.25-4 mg/l for norfloxacin, and 0.06-0.5 mg/l for pefloxacin. These compounds have been shown to be active at similar concentrations also against Staphylococcus epidermidis and both oxacillin-sensitive and resistant Staphylococcus aureus and Staphylococcus epidermidis. Clinical experience (in the order of number of patients treated) has been gathered most extensively with ciprofloxacin, followed by pefloxacin, ofloxacin, norfloxacin, and enoxacin.
Key concepts: Pefloxacin, Norfloxacin, Ofloxacin, Ciprofloxacin, Enoxacin, Microbiology, Staphylococcus epidermidis, Staphylococcus aureus